Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States

INTRODUCTION: Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patients achieving single and composite endpoints, enc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Adv Ther
Autori principali: Hunt, Barnaby, Hansen, Brian B., Ericsson, Åsa, Kallenbach, Klaus, Ali, Sarah N., Dang-Tan, Tam, Malkin, Samuel J. P., Valentine, William J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Healthcare 2019
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6860465/
https://ncbi.nlm.nih.gov/pubmed/31650514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-01125-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi